Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23454359 | 0.83 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL20190440 | 0.82 | CYP1A2 (0.43) | MAPK14 | |
| SCHEMBL22201999 | 0.80 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL23454371 | 0.80 | DGAT1 (0.31) | MAPK14 | |
| SCHEMBL23454241 | 0.80 | DGAT1 (0.31) | MAPK14 | |
| SCHEMBL23454243 | 0.80 | DGAT1 (0.31) | MAPK14 | |
| SCHEMBL4199616 | 0.77 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL25420672 | 0.74 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL11914746 | 0.73 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL23571599 | 0.71 | MEN1 (0.45) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661964-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2024165453-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-15 | — | — | WO | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | MAPK14 72/4885 |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | CCR6, CCR4, CCR1 | MAPK14 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.